Table 1.
Sociodemographic and Clinical Characteristics Data (n=130)
| Variables | N | % |
|---|---|---|
| Age | ||
| Mean±SD | 58.17±9.46 | |
| Median (min-max) | 58.0 (34–75) | |
| ≤65 | 98 | 75.4 |
| >65 | 32 | 24.6 |
| Histology | ||
| Serous adenocarcinoma | 104 | 80 |
| Endometrioid adenocarcinoma | 10 | 7.7 |
| Clear cell adenocarcinoma | 6 | 4.6 |
| Mucinous adenocarcinoma | 10 | 7.7 |
| Tumor location | ||
| Ovary | 111 | 85.3 |
| Fallopian tube | 7 | 5.5 |
| Primary peritoneum | 6 | 4.6 |
| Ovary + Fallopian tube | 6 | 4.6 |
| Stage at diagnosis | ||
| 3a | 16 | 12.3 |
| 3b | 17 | 13.1 |
| 3c | 55 | 42.3 |
| 4a | 13 | 10.0 |
| 4b | 29 | 22.3 |
| Ascite | ||
| No | 68 | 52.3 |
| Yes | 62 | 47.7 |
| Initial surgical status | ||
| Surgery + adjuvant chemotherapy | 43 | 33.1 |
| Neoadjuvant chemotherapy + surgery + adjuvant chemotherapy | 73 | 56.2 |
| In-operable patients | 14 | 10.8 |
| >1 cm. residual disease | ||
| No | 88 | 76.5 |
| Yes | 27 | 23.5 |
| First-line chemotherapy regimen in after recurrence/progression and in metastatic disease | ||
| Carboplatin + gemcitabine + bevacizumab | 54 | 36.2 |
| Carboplatin + paclitaxel + bevacizumab | 56 | 36.9 |
| Carboplatin + liposomal doxorubicin + bevacizumab | 10 | 7.7 |
| Cyclophosphamide + bevacizumab | 10 | 7.7 |
| How many cycles of neoadjuvant therapy | ||
| 3 | 48 | 66.7 |
| 4 | 24 | 33.3 |
| Mortality | ||
| Lives | 42 | 32.3 |
| Exitus | 88 | 67.7 |
| PFS in the first line after recurrence/progression and in the metastatic first line (months) | ||
| Median (min-max) | 10.0 (3.0–24.0) | |
| Follow-up period (months) | ||
| Median (min-max) | 32.0 (9.0–141.0) | |
Abbreviation: PFS, Progression-free survival.